These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38887849)

  • 1. Bioengineered Model of Human LGMD2B Skeletal Muscle Reveals Roles of Intracellular Calcium Overload in Contractile and Metabolic Dysfunction in Dysferlinopathy.
    Khodabukus A; Prabhu NK; Roberts T; Buldo M; Detwiler A; Fralish ZD; Kondash ME; Truskey GA; Koves TR; Bursac N
    Adv Sci (Weinh); 2024 Aug; 11(31):e2400188. PubMed ID: 38887849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.
    Sreetama SC; Chandra G; Van der Meulen JH; Ahmad MM; Suzuki P; Bhuvanendran S; Nagaraju K; Hoffman EP; Jaiswal JK
    Mol Ther; 2018 Sep; 26(9):2231-2242. PubMed ID: 30166241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.
    Gushchina LV; Bhattacharya S; McElhanon KE; Choi JH; Manring H; Beck EX; Alloush J; Weisleder N
    Mol Ther; 2017 Oct; 25(10):2360-2371. PubMed ID: 28750735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice.
    White Z; Sun Z; Sauge E; Cox D; Donen G; Pechkovsky D; Straub V; Francis GA; Bernatchez P
    Skelet Muscle; 2022 Nov; 12(1):25. PubMed ID: 36447272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.
    Poudel BH; Fletcher S; Wilton SD; Aung-Htut M
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models.
    Vallecillo-Zúniga ML; Rathgeber MF; Poulson PD; Hayes S; Luddington JS; Gill HN; Teynor M; Kartchner BC; Valdoz J; Stowell C; Markham AR; Arthur C; Stowell S; Van Ry PM
    PLoS One; 2020; 15(9):e0238441. PubMed ID: 32881965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysferlin mutations and mitochondrial dysfunction.
    Vincent AE; Rosa HS; Alston CL; Grady JP; Rygiel KA; Rocha MC; Barresi R; Taylor RW; Turnbull DM
    Neuromuscul Disord; 2016 Nov; 26(11):782-788. PubMed ID: 27666772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B.
    Sellers SL; Milad N; White Z; Pascoe C; Chan R; Payne GW; Seow C; Rossi F; Seidman MA; Bernatchez P
    J Lipid Res; 2018 Feb; 59(2):261-272. PubMed ID: 29175948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diltiazem improves contractile properties of skeletal muscle in dysferlin-deficient BLAJ mice, but does not reduce contraction-induced muscle damage.
    Begam M; Collier AF; Mueller AL; Roche R; Galen SS; Roche JA
    Physiol Rep; 2018 Jun; 6(11):e13727. PubMed ID: 29890050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot investigations into the mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy.
    Lloyd EM; Crew RC; Haynes VR; White RB; Mark PJ; Jackaman C; Papadimitriou JM; Pinniger GJ; Murphy RM; Watt MJ; Grounds MD
    Skelet Muscle; 2024 Aug; 14(1):19. PubMed ID: 39123261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B.
    Hogarth MW; Defour A; Lazarski C; Gallardo E; Diaz Manera J; Partridge TA; Nagaraju K; Jaiswal JK
    Nat Commun; 2019 Jun; 10(1):2430. PubMed ID: 31160583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B.
    Bittel DC; Sreetama SC; Chandra G; Ziegler R; Nagaraju K; Van der Meulen JH; Jaiswal JK
    J Clin Invest; 2022 Jan; 132(1):. PubMed ID: 34981776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myofibers deficient in connexins 43 and 45 expression protect mice from skeletal muscle and systemic dysfunction promoted by a dysferlin mutation.
    Fernández G; Arias-Bravo G; Bevilacqua JA; Castillo-Ruiz M; Caviedes P; Sáez JC; Cea LA
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165800. PubMed ID: 32305450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compound heterozygous DYSF variants causing limb-girdle muscular dystrophy type 2B in a Chinese family.
    Li L; Jing Z; Cheng L; Liu W; Wang H; Xu Y; Zheng X; Yu X; Liu S
    J Gene Med; 2020 Nov; 22(11):e3272. PubMed ID: 32889728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysferlin function in skeletal muscle: Possible pathological mechanisms and therapeutical targets in dysferlinopathies.
    Cárdenas AM; González-Jamett AM; Cea LA; Bevilacqua JA; Caviedes P
    Exp Neurol; 2016 Sep; 283(Pt A):246-54. PubMed ID: 27349407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice.
    Llanga T; Nagy N; Conatser L; Dial C; Sutton RB; Hirsch ML
    Mol Ther; 2017 Sep; 25(9):2150-2162. PubMed ID: 28629822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMPK Complex Activation Promotes Sarcolemmal Repair in Dysferlinopathy.
    Ono H; Suzuki N; Kanno SI; Kawahara G; Izumi R; Takahashi T; Kitajima Y; Osana S; Nakamura N; Akiyama T; Ikeda K; Shijo T; Mitsuzawa S; Nagatomi R; Araki N; Yasui A; Warita H; Hayashi YK; Miyake K; Aoki M
    Mol Ther; 2020 Apr; 28(4):1133-1153. PubMed ID: 32087766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysferlin protein analysis in limb-girdle muscular dystrophies.
    Vainzof M; Anderson LV; McNally EM; Davis DB; Faulkner G; Valle G; Moreira ES; Pavanello RC; Passos-Bueno MR; Zatz M
    J Mol Neurosci; 2001 Aug; 17(1):71-80. PubMed ID: 11665864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane.
    Kerr JP; Ziman AP; Mueller AL; Muriel JM; Kleinhans-Welte E; Gumerson JD; Vogel SS; Ward CW; Roche JA; Bloch RJ
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20831-6. PubMed ID: 24302765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B.
    White Z; Milad N; Tehrani AY; Chen WW; Donen G; Sellers SL; Bernatchez P
    PLoS One; 2019; 14(8):e0220903. PubMed ID: 31404091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.